Published in Clin Exp Immunol on November 01, 2004
IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med (2012) 2.11
Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology (2006) 1.43
Significance of IL-1RA Polymorphism in Iranian Patients with Inflammatory Bowel Disease. Dig Dis Sci (2014) 1.38
Crohn's disease: NOD2, autophagy and ER stress converge. Gut (2011) 1.27
Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Front Immunol (2013) 1.11
Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol (2009) 1.10
Upregulation of RGS4 and downregulation of CPI-17 mediate inhibition of colonic muscle contraction by interleukin-1beta. Am J Physiol Cell Physiol (2007) 1.08
Immunoregulatory protein profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in preterm infants. PLoS One (2012) 0.96
IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics (2012) 0.90
The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. Br J Pharmacol (2007) 0.88
IL-1 and T Helper Immune Responses. Front Immunol (2013) 0.87
Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis. Clin Exp Immunol (2011) 0.84
Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition. Arthritis Res Ther (2013) 0.81
Effects of obesity on severity of colitis and cytokine expression in mouse mesenteric fat. Potential role of adiponectin receptor 1. Am J Physiol Gastrointest Liver Physiol (2015) 0.81
IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer. Cancer Microenviron (2015) 0.80
Secreted protein acidic and rich in cysteine (SPARC) exacerbates colonic inflammatory symptoms in dextran sodium sulphate-induced murine colitis. PLoS One (2013) 0.78
The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications. Dig Dis Sci (2016) 0.77
Interleukin-18 is increased only in a minority of patients with active Crohn's disease. Int J Colorectal Dis (2007) 0.77
Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol (2016) 0.77
Bioluminescence imaging for IL-1β expression in experimental colitis. J Inflamm (Lond) (2013) 0.77
The IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case-control study. World J Urol (2014) 0.76
Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. Mucosal Immunol (2015) 0.76
Regulation of Neutrophil Degranulation and Cytokine Secretion: A Novel Model Approach Based on Linear Fitting. J Immunol Res (2015) 0.75
Interleukin-1 associations in inflammatory bowel disease and the enteropathic seronegative spondylarthritis. Auto Immun Highlights (2013) 0.75
Vitamin D differentially regulates Salmonella-induced intestine epithelial autophagy and interleukin-1β expression. World J Gastroenterol (2016) 0.75
Stricture of ileo-anal J pouch anastomosis increased the intensity of pouchitis in an experimental rat model. Med Sci Monit (2012) 0.75
Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice. Front Immunol (2016) 0.75
Epithelial Cell Inflammasomes in Intestinal Immunity and Inflammation. Front Immunol (2017) 0.75
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature (1990) 5.86
Inflammatory bowel disease (1) N Engl J Med (1991) 5.78
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut (1989) 4.59
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (1989) 4.13
Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology (1994) 3.60
Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol (1990) 3.54
The role of interleukin-1 in disease. N Engl J Med (1993) 3.45
Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol (1995) 2.71
Interleukin-1 receptor antagonist. Adv Immunol (1993) 2.58
Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem (1995) 2.58
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet (1997) 2.38
Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A (1996) 2.18
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today (2000) 2.09
Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem (1991) 1.78
Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology (1993) 1.75
The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity (2003) 1.61
Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol (1994) 1.61
Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA (1993) 1.54
Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest (1994) 1.53
IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol (1994) 1.48
Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood (1991) 1.43
Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology (1999) 1.35
Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A (1995) 1.32
The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J Immunol (1998) 1.29
Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem (1990) 1.25
Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med (1991) 1.21
IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol (2000) 1.19
A soluble form of the interleukin-1 receptor produced by a human B cell line. FEBS Lett (1990) 1.17
The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest (1995) 1.15
Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology (1998) 1.10
Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol (1994) 1.10
Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin Invest (1990) 1.07
Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut (2000) 1.02
Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum (1991) 1.00
Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett (1997) 1.00
Physiologic role of interleukin-1 receptor antagonist. Arthritis Res (2000) 0.97
Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol (1998) 0.93
Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum (1998) 0.91
Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion (2001) 0.91
Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood (1996) 0.86
Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. Curr Opin Clin Nutr Metab Care (2000) 0.79
Interleukin-1. Rev Infect Dis (1984) 11.24
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 10.92
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A (1984) 8.84
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest (1988) 5.22
Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med (1984) 5.12
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science (1986) 4.25
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest (1998) 3.54
Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med (1983) 3.49
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. Cell Immunol (1981) 3.22
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A (2001) 3.21
Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A (1977) 3.15
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest (1986) 3.05
Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med (1974) 2.98
An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol (1985) 2.90
Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science (1988) 2.87
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 2.86
Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med (1985) 2.84
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest (2001) 2.84
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science (1986) 2.83
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest (1986) 2.82
Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol (1999) 2.79
Lymphokines. N Engl J Med (1987) 2.77
Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum (1983) 2.75
Molecular basis of fever in humans. Am J Med (1982) 2.69
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68
Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med (1979) 2.64
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A (1999) 2.57
A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J (1991) 2.52
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol (1989) 2.41
Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol (2001) 2.41
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science (1991) 2.37
Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med (1974) 2.35
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest (1984) 2.33
Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. Am J Pathol (1987) 2.27
A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A (1988) 2.22
Interleukin-1 immunoreactive innervation of the human hypothalamus. Science (1988) 2.22
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest (1986) 2.21
Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J Immunol (1983) 2.20
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest (1991) 2.17
Multiple biological activities of human recombinant interleukin 1. J Clin Invest (1986) 2.16
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol (2001) 2.16
Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A (2000) 2.14
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol (1985) 2.14
Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract (2010) 2.12
Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun (2003) 2.10
Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. J Immunol (1997) 2.10
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today (2000) 2.09
Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet (1993) 2.05
The effects of interleukin 1 on human B cell activation and proliferation. J Immunol (1983) 2.05
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A (2000) 2.03
Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest (1994) 2.01
Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J Neurochem (1981) 1.99
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98
Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A (2001) 1.97
Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation (1999) 1.94
Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. Clin Immunol Immunopathol (1988) 1.93
Effect of endotoxin in IL-1 beta-deficient mice. J Immunol (1996) 1.92
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut (2005) 1.91
Leptin deficiency enhances sensitivity to endotoxin-induced lethality. Am J Physiol (1999) 1.90
Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. Fed Proc (1987) 1.90
Interleukin-1 stimulates diacylglycerol production in T lymphocytes by a novel mechanism. Cell (1988) 1.89
Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol (1986) 1.87
Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem (1991) 1.86
IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A (2000) 1.86
Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. J Clin Invest (1979) 1.85
The production of antibody against human leukocytic pyrogen. J Clin Invest (1977) 1.84
Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med (1988) 1.82
Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). Year Immunol (1986) 1.81
Mechanisms of fever induced by recombinant human interferon. J Clin Invest (1984) 1.81
Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol (2000) 1.80
Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci (1998) 1.79
A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol (1995) 1.76
Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. Immunology (1991) 1.76